Specially selected anatomical fixation implants matching the clinical standard of Southern Cross Hospitals and District Health Boards (Te Whatu Ora).
New Zealand's orthopedic trauma space operates within a highly regulated public-private framework. The public sector, unified under Te Whatu Ora (Health New Zealand), works alongside private hospital groups like Southern Cross Healthcare, MercyAscot, and Evolution Healthcare to address traumatic injuries from sports, agriculture, and high-velocity road accidents. For procurement managers, finding cost-effective, bio-compatible osteosynthesis implants that comply with Medsafe standards is essential to managing tight healthcare budgets.
Before any orthopedic medical device can be sold or utilized within New Zealand, it must be notified to the WAND (Web-based Database of Medical Devices) system operated by Medsafe. Implants such as locking plates, intramedullary nails, and compression screws are classified as Class IIb or Class III medical devices. Importers must work with a designated New Zealand Sponsor. Moventra provides full technical dossiers, including biocompatibility reports, ISO 13485 certifications, CE mark certificates, and mechanical testing profiles, ensuring a smooth registration pathway for distributors.
Modern traumatology demands materials that balance strength, fatigue resistance, and biocompatibility. Moventra utilizes premium grade raw materials:
New Zealand's aging population presents a rise in fragility fractures, particularly of the proximal femur and distal radius. The demand for advanced locking compression plates (LCP) and dynamic hip screws (DHS) is growing. Modern locking screw technology provides angular stability, which is vital for securing osteoporotic bone where conventional cortical screws might fail.
Bridging precision engineering with medical standards to deliver OEM and ODM services worldwide.
| Specification Parameter | Details & Audit Scope |
|---|---|
| Company Registered Name | Moventra Medical Technology (China) Co., Ltd. |
| Manufacturing Facility Area | 18,600 m² (Including Class 100,000 Cleanroom Packaging lines) |
| Quality Control Staff | 48 Dedicated QC Inspectors and Metrology Engineers |
| Annual Export Output Value | USD 23.8 Million |
| Testing Capabilities | Dimensional Inspection, Material Analysis, Surface Finish Inspection, Mechanical Performance Testing, Sterility Verification |
| Design Capabilities | SolidWorks/ANSYS CAD/FEA simulation modeling, rapid 3D prototyping, customized OEM/ODM development |
| Global Certifications | ISO 13485 Quality Management Systems, CE Mark, Regulatory Dossier Support |
Step inside our manufacturing plant featuring advanced Swiss-type CNC machines, milling centers, and micro-hardness testing labs.
New Zealand's isolated geography presents logistics challenges for healthcare suppliers. During regional or global crises, lead times can impact clinical care. Moventra partners with distributors to safeguard inventory and reduce freight times, ensuring hospitals maintain critical trauma stock levels.
By establishing buffer stocks of key trauma sizes, such as 3.5 mm Clavicle Plates and standard DHS systems, distributors can mitigate sudden spikes in emergency hospital demand. We support distributors with low MOQ arrangements, enabling they hold a complete range of anatomical options.
Implants require matching instruments. Moventra manufactures and supplies complete surgical instrument kits, including specialized drills, guides, and screwdrivers, designed to fit our locking plate and nail systems. This compatibility simplifies training for theatre nurses and orthopedic registrars.
With 86 R&D engineers, we collaborate with global medical brands to develop customized locking shapes and surface treatments (e.g., Type II anodization for titanium). This enables distributors to introduce tailored trauma lines to the market under their own private brands.
Examine our range of orthopedic implants, manufactured to meet ISO 13485 standards for trauma and fracture reconstruction.
The global orthopedic market is moving toward smart implants and additive manufacturing. Moventra's R&D team focuses on three key areas to support future requirements in New Zealand and globally:
We are refining electrochemical processes to produce microporous surfaces on titanium implants. These modifications help accelerate osteoblast adhesion, shortening recovery times for complex tibial and femoral reconstructive surgeries.
To reduce the need for secondary surgeries to remove hardware, particularly in pediatric patients, we are researching magnesium alloy compositions. These materials are designed to gradually degrade and absorb as the bone heals.
For complex cases with significant bone loss, we utilize selective laser melting (SLM) to produce patient-specific titanium implants. This technology enables surgeon-led customization matching precise CT-scan geometries.
Addressing technical, regulatory, and commercial inquiries from medical distributors and surgical centers.
Moventra Medical
